Annovis Bio (ANVS) Projected to Post Quarterly Earnings on Friday

Annovis Bio (NYSE:ANVS) is expected to release its earnings data before the market opens on Friday, April 4th. Analysts expect Annovis Bio to post earnings of ($0.38) per share for the quarter.

Annovis Bio (NYSE:ANVS) last posted its quarterly earnings results on Friday, March 21st. The company reported ($0.43) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.38) by ($0.05). During the same quarter last year, the company posted ($0.43) earnings per share. On average, analysts expect Annovis Bio to post $-2 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Annovis Bio Price Performance

ANVS stock opened at $1.60 on Thursday. Annovis Bio has a one year low of $1.43 and a one year high of $20.00. The stock has a market cap of $22.78 million, a price-to-earnings ratio of -0.36 and a beta of 1.65. The company has a fifty day moving average price of $2.47 and a two-hundred day moving average price of $5.38.

Analysts Set New Price Targets

Separately, D. Boral Capital restated a “hold” rating on shares of Annovis Bio in a research note on Monday, February 10th. One equities research analyst has rated the stock with a hold rating, four have issued a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Buy” and an average price target of $37.00.

Annovis Bio Company Profile

Annovis Bio, Inc, a clinical stage drug platform company, develops drugs to treat neurodegeneration. The company's lead product candidate is Buntanetap, which has completed three Phase 1/2 clinical trials for the treatment of Alzheimer's disease (AD), Parkinson's disease, and other chronic neurodegenerative diseases.